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Effect of type II endoleaks and antiplatelet therapy
on abdominal aortic aneurysm shrinkage after
endovascular repair
Atsushi Aoki, MD,a Takanori Suezawa, MD,a Kenji Sangawa, MD,b and Mamoru Tago, MD,a
Kagawa and Matsuyama, Japan
Objective: Endovascular repair of abdominal aortic aneurysm (EVAR) has been shown to be safe, and its use is increasing
rapidly, but the long-term results of this procedure remain unclear. A decrease in the diameter of the aneurysm sac is
considered to represent successful exclusion of the aneurysm from the circulation, but it has been reported that aneurysm
shrinkage occurs in only about 60% of patients who have undergone EVAR. We analyzed several factors to determine
whether they were related to aneurysm shrinkage after EVAR.
Methods: From March 2007 to January 2010, EVAR was performed in 65 patients, 58 of whom underwent an
enhanced computerized tomographic evaluation 6 months after the procedure. One patient was found to have a type
Ia endoleak and was excluded from the study. In the remaining 57 patients, univariate and multiple regression
analyses were used to determine whether there was a relationship between aneurysm shrinkage and various patient
characteristics, aneurysm dimensions, and procedural outcomes. Aneurysm shrinkage was defined as a decrease in
diameter of at least 4 mm.
Results: On univariate analysis, a lack of aneurysm shrinkage by 7 days and 6 months after EVAR was significantly
associated with hyperlipidemia, ongoing multiagent antiplatelet therapy with clopidogrel, ticlopidine, or cilostazol as
well as aspirin, length of the proximal neck of the aneurysm, preproceduremaximum aneurysm diameter, and the presence
of a type II endoleak. On multiple regression analysis, only multiagent antiplatelet therapy and type II endoleak were
significantly related to a lack of aneurysm shrinkage 6 months after EVAR. Multiagent antiplatelet therapy and type II
endoleak 6 months after EVAR were not significantly associated with each other.
Conclusion: Patients with a persistent type II endoleak and patients undergoing multiagent antiplatelet therapy are at an
increased risk of a lack of aneurysm shrinkage 6 months after EVAR. (J Vasc Surg 2011;54:947-51.)
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tRandomized trials have shown that endovascular repair
of abdominal aortic aneurysm (EVAR) yields favorable
short-term results, with mortality rates significantly lower
than those associated with surgical repair.1,2 EVAR is now
widely and increasingly used. The goal of an EVAR proce-
dure is to prevent rupture by excluding the aneurysm from
the circulation. A decrease in the size of the aneurysm sac is
considered to represent successful exclusion of the aneu-
rysm from the circulation.3,4However, aneurysm shrinkage
has been reported to occur in only about 60% of patients
who have undergone EVAR5; therefore, the long-results of
the procedure remain controversial. We investigated factors
that might influence aneurysm shrinkage after EVAR.
METHODS
From March 2007 to January 2010, 65 patients with
an atherosclerotic abdominal aortic aneurysm (AAA)
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doi:10.1016/j.jvs.2011.03.269nderwent EVAR at our institutions. Fifty-eight of these
atients had an enhanced computerized tomographic
CT) evaluation 6 months after the procedure. One
atient was found to have a type Ia endoleak and was
xcluded from further investigation. The remaining 57
atients (49 men, 8 women; mean age, 76 years [range,
7-92 years]) were enrolled in the study.
The variables that were analyzed with respect to their
ossible effect on aneurysm shrinkage included patient
emographics and concomitant diseases, aneurysm char-
cteristics, and the presence of a type II endoleak after
VAR (Table I). All the patients in the study who had
ypertension or hyperlipidemia were receiving medical
reatment for their condition. The 20 patients with coro-
ary artery disease had previously undergone percutaneous
oronary intervention or coronary artery bypass grafting.
he 23 patients receiving antiplatelet therapy had a his-
ory of coronary artery disease (14 patients) or cerebral
essel attack (9 patients). Fourteen of the 23 were taking
ither clopidogrel bisulfate, ticlopidine hydrochloride,
r cilostazol, as well as aspirin. Three patients were receiv-
ng warfarin potassium as anticoagulation therapy, two for
hronic atrial fibrillation, and one because of a history of
itral valve replacement with a mechanical valve. We did
ot conduct analyses based on the type of anticoagulation
herapy because of the small number of patients receiving
his treatment.
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II endoleaks: completion angiography at the time of the
EVAR procedure and enhanced CT scanning 7 days and 6
months afterward. To mitigate measurement error, aneu-
rysm sac shrinkage was defined as a decrease of at least 4
mm in maximum sac diameter.6
Nonpaired t testing, 2 testing, and regression analysis
were used for univariate analysis of factors possibly associ-
ated with a lack of aneurysm shrinkage. Multiple regression
Table I. Results of univariant analysis of factors possibly a
57 patients
Variable
Patient characteristics
Age
Gender
F (n  8)
M (n  49)
Hypertension
Absent (n  13)
Present (n  44)
Hyperlipidemia
Absent (n  40)
Present (n  17)
Diabetes mellitus (type I or II)
Absent (n  45)
Present (n  12)
Chronic obstructive pulmonary disease
Absent (n  52)
Present (n  5)
Smoking status
Nonsmoker (n  21)
Current smoker (n  36)
Coronary artery disease
Absent (n  37)
Present (n  20)
Antiplatelet therapy (including aspirin only)
Not receiving (n  34)
Receiving (n  23)
Multiagent antiplatelet therapyb
Not receiving (n  43)
Receiving (n  14)
Type of endoprosthesisc
Zenith (n  31)
Powerlink (n  4)
Excluder (n  22)
Aneurysm characteristics
Proximal neck length
Angle
Maximum diameter
Type II endoleak on EVAR completion angiogram
No (n  40)
Yes (n  17)
7 days after EVAR (enhanced CT)
No (n  41)
Yes (n  16)
6 months after EVAR (enhanced CT)
No (n  43)
Yes (n  14)
CT, Computerized tomographic scanning; EVAR, endovascular aneurysm
aPlus-minus values are mean  SD millimeters of shrinkage.
bIncluded both aspirin and either clopidogrel, ticlopidine, or cilostazol.
cThe manufacturers are Cook, Bloomington, Ind (Zenith); Endologix, Irvianalysis was used for multivariant assessments. A P value of cess than .05 was considered to represent a significant
orrelation. All analyses were done with StatView 5 soft-
are (SAS Institute, Cary, NC).
ESULTS
During the study period, no AAA ruptures occurred,
nd no reinterventions to treat a type II endoleak were
equired. On admission, blood pressure values in pa-
ients with a history of hypertension were not signifi-
ated with aneurysm shrinkage at 6 months after EVAR in
Results a P value
y  0.1  0.8x, r  0.012 .449
.388
7.6  4.5
5.7  6.0
.347
7.3  5.8
5.6  5.8
.043
7.0  6.2
3.6  4.2
.938
5.9  5.7
6.1  6.5
.623
5.8  5.8
7.2  5.9
.962
6.2  6.4
6.1  5.3
.470
6.4  5.9
5.2  5.8
.163
7.3  5.9
4.7  5.5
.003
7.3  5.9
2.0  3.2
.758
5.7  5.7
2.8  2.6
6.9  6.3
y  10.3-0.16x, r  0.281 .034
y  5.0  0.23x, r  0.084 .533
y  3.0  0.17x, r  0.314 .017
.860
6.2  6.1
6.2  6.1
.039
7.0  6.3
3.4  3.3
.001
7.5  5.9
1.4  1.9
lif (Powerlink); and W. L. Gore & Associates, Flagstaff, Ariz (Excluder).ssoci
repair.antly different from those in patients without such a
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Volume 54, Number 4 Aoki et al 949history (mean  SD, 125  15/73 10mmHg vs 118
8/69  8 mm Hg; P  .22 for systolic and .24 for
diastolic value).
Table I shows the mean ( SD) millimeters of aneu-
rysm shrinkage at 6 months according to the factors inves-
tigated, as well as the results of the univariate analysis.
Among the 17 patients found to have a type II endoleak on
completion angiography at the time of endovascular aneu-
rysm repair (EVAR), 10 did not have an endoleak on
enhanced computerized tomographic (CT) scanning 7
days after the procedure. In nine other patients, a type II
endoleak was newly detected at 7 days. Therefore, at 7 days
after EVAR, 16 patients (28% of all those in the study) had
a type II endoleak. Six of these 16 patients did not have a
type II endoleak 6 months after EVAR, but four other
patients did; therefore, 14 patients (25%) had a type II
endoleak 6 months after EVAR.
The univariate analysis revealed that the following fac-
tors were significantly associated with a lack of aneurysm
shrinkage 6 months after EVAR: hyperlipidemia, multi-
agent antiplatelet therapy, long aneurysm proximal neck,
small preoperative maximum aneurysm diameter, and type
II endoleak detected on enhanced CT scanning 7 days or 6
months after EVAR. Onmultiple regression analysis (Table
II), only multiagent antiplatelet therapy and type II en-
doleak detected 6 months after EVAR were significantly
related to a lack of aneurysm shrinkage at 6 months.
There was no significant difference between patients
Table II. Results of multiple regression analysis of
factors possibly associated with aneurysm shrinkage at 6
months after EVAR in 57 patients
Variable r Error t value P value
Age 0.043 0.107 0.406 .687
Gender 1.217 2.302 0.529 .600
Hypertension 0.147 1.768 0.083 .934
Hyperlipidemia 1.468 1.811 0.811 .423
Diabetes mellitus 0.726 1.808 0.402 .690
Chronic obstructive
pulmonary disease 1.650 2.389 0.699 .489
Smoking 0.668 1.574 0.425 .674
Antiplatelet therapy
(aspirin) 1.522 1.875 0.812 .422
Multiagent antiplatelet
therapya 5.344 2.133 2.506 .017
Aneurysm proximal
neck length 0.033 0.089 0.365 .717
Aneurysm angle 0.010 0.039 0.268 .790
Aneurysm diameter 0.105 0.072 1.458 .153
Type of
endoprosthesis 2.038 1.261 1.616 .114
Type II endoleak at
EVAR 1.786 1.649 1.083 .286
Type II endoleak 7
days after EVAR 1.171 1.914 0.612 .544
Type II endoleak 6
months after EVAR 5.708 2.103 2.714 .010
EVAR, Endovascular aneurysm repair.
aIncluded both aspirin and either clopidogrel, ticlopidine, or cilostazol.receiving multiagent antiplatelet therapy and those not meceiving this treatment in the frequency of type II en-
oleaks 6 months after EVAR (29% vs 30%). Also at 6
onths after EVAR, 32 patients were neither undergoing
ultiagent antiplatelet therapy nor found to have a type II
ndoleak. In these patients, the amount of aneurysm sac
hrinkage was significantly greater than it had been 7 days
fter EVAR (9.2 5.6 mm at 6 months vs 3.3 3.5 mm at
days; P .001; Fig). However, the aneurysm sac did not
hrink in patients who had a type II endoleak detected 6
onths after EVAR and were not receiving multiagent
ntiplatelet therapy or in patients with or without a type II
ndoleak who were undergoing multiagent antiplatelet
herapy.
ISCUSSION
It has been reported that a reduction in aneurysm
olume of more than 10% by 6 months after EVAR is
redictive of good long-term results.3 Moreover, a 75%
eduction in the difference between the largest diameter of
he aneurysm and the diameter of the stent graft body has
een observed to be predictive of durable results after
VAR.4 However, it has also been found that aneurysm
hrinkage occurs in only 60% of patients who undergo
VAR and that the aneurysm diameter either does not
hange or increases in the remaining 40%.5 In this study, we
bserved a shrinkage in aneurysm sac diameter of more
han 4 mm in 51% of patients who had undergone EVAR.
nivariate analysis indicated that lack of aneurysm shrink-
ge was associated with aneurysms that had a long proximal
eck or small preprocedure diameter, hyperlipidemia, and
ngoing multiagent antiplatelet therapy but not antiplate-
et therapy using aspirin only. Type II endoleaks detected
y completion angiography at the time of EVAR had no
elationship with aneurysm shrinkage, whereas type II en-
oleaks identified by enhanced CT scanning 7 days or 6
ig. Aneurysm shrinkage at 7 days and 6 months after endovas-
ular abdominal aortic aneurysm repair (EVAR) in patients with a
ype II endoleak who were receiving multiagent antiplatelet ther-
py (APT) (n 3), patients with a type II endoleak who were not
eceiving APT (n  11), patients without a type II endoleak who
ere receiving APT (n  11), and patients without a type II
ndoleak who were not receiving APT (n  32). Error bars
epresent mean  SD.onths after EVAR were correlated with a lack of shrink-
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October 2011950 Aoki et alage. Multivariant analysis found that the presence of a type
II endoleak 6months after EVAR andmultiagent antiplate-
let therapy were each significantly related to a lack of
aneurysm sac reduction.
The presence of a type I or type III endoleak is a known
risk factor for expansion and rupture of an aneurysm, and
intervention is required if one of these “high-pressure”
endoleaks is detected.6-8 The importance of type II en-
doleaks, however, remains unknown. Some studies have
found that type II endoleaks do not increase the risk of
aneurysm rupture or conversion to open surgical repair,9,10
whereas another investigation concluded that type II en-
doleaks are associated with a need for open surgery.7 Cur-
rently, the consensus is that treatment of a type II endoleak
should be considered when the aneurysm sac has ex-
panded.11
The variations in findings regarding the effect of type II
endoleaks on the long-term results of EVARmay be at least
partly due to the possible existence of several type II en-
doleak subgroups. Some type II endoleaks seal without
intervention,9,10,12-14 and those that disappear within 6
months after EVAR have been classified as transient,
whereas those present for a longer period are designated
persistent. Jones et al14 reported that persistent type II
endoleaks, but not transient type II endoleaks, represent a
risk factor for aneurysm expansion and rupture. Arko et al12
found that aneurysms in patients with a persistent type II
endoleak did not shrink, whereas those in patients with a
transient type II endoleak did. Hiatt and Rubin15 divided
type II endoleaks into “simple” and “complex.” In patients
with a simple type II endoleak, only one artery is connected
to the aneurysm; in those with a complex type II endoleak,
two or more arteries feed and/or drain the aneurysm.
Type II endoleaks also have differing hemodynamic
characteristics. Bargellini et al16 used contrast-enhanced
ultrasonography to measure the interval between injection
of the contrast medium and endoleak detection. Type II
endoleaks were classified as either hyperdynamic (wash-in
period,100 s) or hypodynamic (wash-in period,100 s).
The researchers found that hypodynamic type II endoleaks,
especially those with a washout time of more than 520 s,
were associated with aneurysm expansion. Because these
endoleaks had no drainage vessels, the pressure within the
aneurysm sac was probably high. Dias et al17 measured
intrasac pressure in patients with endoleaks by using direct
puncture. They then calculated a sac pressure index (SPI) as
the ratio between the intrasac pressure and systemic pres-
sure. The researchers found that in patients with a type II
endoleak, the SPI ranged from 22% to 87%. Aneurysm
shrinkage was associated with an SPI of 35% or less, whereas
an SPI value of 74% to 78% was related to no reduction or
expansion of the aneurysm.
The mechanism by which type II endoleaks seal spon-
taneously is formation of thrombus in the aneurysm sac that
results in occlusion of the feeding artery. However, the
structure of thrombi and the pressure within them
vary.17,18 Vellabhaneni et al18 assessed the relationship
between the histologic features of a thrombus and the eransmission of pressure through it by studying thrombi
emoved during open abdominal aortic aneurysm (AAA)
epair. They found that pressure transmission was inversely
orrelated with the matrix density of a thrombus. Thus,
hen the matrix density was 97%, the pressure transmission
as 6%, but when the matrix density was 52%, the pressure
ransmission was 100%. In our study, the aneurysm sac did
ot shrink in patients undergoing multiagent antiplatelet
herapy. This finding suggests that the thrombus in the
neurysm sac in these patients did not become “hard”
ecause of the disruption of coagulation mechanisms
aused by the treatment.
Enhanced CT scanning is widely used to detect en-
oleaks, and the sensitivity and specificity of this method
ave been reported to be as high as 92% and 90%, respec-
ively.15 Enhanced CT scanning cannot, however, identify
ll endoleaks. Bargellini et al16 reported that of 18 en-
oleaks detected by using contrast-enhanced ultrasonogra-
hy, enhanced CT scanning found only 10. Expansion of
n aneurysm sac in the absence of an endoleak on enhanced
T scanning is termed endotension. Endotension may
ctually represent a small endoleak that is undetectable by
nhanced CT scanning.
Thrombus formation in an aneurysm sac depends on
he relationship between coagulation and fibrinolysis. An-
iplatelet therapy suppresses blood coagulation and throm-
us formation in the sac and may also prevent thrombus
rganization. These actions may have been responsible for
he significant correlation between multiagent antiplate-
et therapy and a lack of aneurysm sac shrinkage after
VAR in the patients in our study.
With respect to the possible effects of anticoagulation
herapy after EVAR, Biebl et al19 observed that long-term
reatment with warfarin was safe and that spontaneous
ndoleak resolution could occur in patients undergoing
uch therapy. In contrast, Bobadilla et al20 found that
arfarin therapy increased the risk of development of en-
oleaks, especially type II endoleaks. We could not evaluate
he effect of anticoagulation therapy on aneurysm sac
hrinkage in our series because of the small number of
atients who were receiving this treatment, and this clearly
epresents a limitation of our study.
Embolization by means of transarterial21 or direct22
uncture has been advocated for treating type II en-
oleaks when aneurysm expansion has occurred. Open
urgery is currently the only available treatment for
xpansion of the aneurysm sac caused by endotension.
owever, discontinuing all antiplatelet therapy except
spirin, if possible because lack of aneurysm shrinkage was
ot associated with aspirin-only therapy in this study, or
dministering an agent that enhances coagulation or sup-
resses fibrinolysis might accelerate thrombosis in the an-
urysm sac and thereby avoid an endotension-related in-
rease in aneurysm size.
The authors thank Renée J. Robillard, MA, ELS, for
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